Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
770.00
-1.12 (-0.15%)
Official Closing Price
Updated: 7:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
December 04, 2023
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet.
Via
MarketBeat
Topics
Bonds
Exposures
Debt Markets
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
November 29, 2023
Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis.
Via
SBWire
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
November 29, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Eli Lilly and Company (NYSE: LLY) is a Leading Gainer in Thursday Morning Trading
November 02, 2023
Via
Investor Brand Network
These are the top sectors for blue chip growth in 2024
November 29, 2023
The sector results will be mixed in 2024 but the Health Care, Communications and Technology sectors (and some of their stocks) will post robust gains.
Via
MarketBeat
Topics
Economy
Intellectual Property
Exposures
COVID-19
Intellectual Property
Interest Rates
Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029
November 17, 2023
EQNX::TICKER_START (OTCPK:CNER),(NASDAQ:PODD),(NASDAQ:TNDM),(NYSE:LLY),(NYSE:ABT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Eli Lilly and Company (NYSE: LLY) is a Stock Spotlight on 10/25
October 25, 2023
Via
Investor Brand Network
Eli Lilly and Company (NYSE: LLY) is a Leading Gainer in Friday Morning Trading
October 06, 2023
Via
Investor Brand Network
Eli Lilly and Company (NYSE: LLY) is a Stock Spotlight on 10/5
October 05, 2023
Via
Investor Brand Network
Type 1 Diabetes Market Comprehensive Study Explores Huge Growth by Key Players DiaVacs, XOMA Corp., Biodel, Macrogenics
November 14, 2023
Type 1 Diabetes Market Growth
Via
SBWire
Exposures
COVID-19
MarketBeat Week in Review – 11/6 - 11/10
November 11, 2023
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Will Eli Lilly's Zepbound be the next big weight-loss drug?
November 10, 2023
Eli Lilly got regulators' OK for weight-loss drug Zepbound, which will compete with Novo Nordisk's Wegovy. Analysts see Zepbound sales as high as $37 billion
Via
MarketBeat
Investor patience tested as pharmaceutical stocks take a tumble
November 01, 2023
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector
Via
MarketBeat
J&J stock down as business unit mulls talc-related bankruptcy
October 31, 2023
Johnson & Johnson stock fell in the past week as talc-related lawsuits weigh on a subsidiary, which is mulling bankruptcy to mitigate payouts and settlements.
Via
MarketBeat
Topics
Bankruptcy
Lawsuit
Exposures
Financial
Legal
Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694
October 25, 2023
Calgary, Alberta--(Newsfile Corp. - October 25, 2023) - Zenith Epigenetics Ltd. ("Zenith" or the "Company"), a global leader in epigenetics,...
Via
Newsfile
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
October 23, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing
October 23, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Is the Ozempic-Driven DexCom Selloff Overdone?
October 18, 2023
Has glucose monitor maker DexCom corrected too much on fears of lost sales due to weight loss and diabetes drugs made by Novo Nordisk and Eli Lilly?
Via
MarketBeat
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
October 17, 2023
Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to...
Via
PressReach
Bristol Myers Squibb Joins Big Pharma’s Race to Dominate Oncology
October 17, 2023
Leading pharmaceutical companies are diving headfirst into oncology, sparking a buzz in the cancer treatment world. Bristol Myers Squibb is the latest company to join the movement, announcing its plan...
Via
PressReach
Eli Lilly and Company (NYSE: LLY) Sets New 52-Week High in Friday Session
October 13, 2023
Via
Investor Brand Network
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
October 13, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Will Higher Ozempic Use Mean Slimmed-Down Food Sales?
October 12, 2023
Novo Nordisk's Ozempic, a weight loss drug, is making waves in the food industry, raising concerns about its effect on sales of calorie-laden products.
Via
MarketBeat
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
October 10, 2023
Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant...
Via
PressReach
Big Pharma’s Billion-Dollar Bets on Advanced Cancer Therapies
October 10, 2023
Big Pharma is continuing its oncology buying spree, with a flurry of multi-billion-dollar deals, partnerships, and investments creating a buzz in the cancer treatment space. American pharmaceutical...
Via
PressReach
Exposures
COVID-19
Elsevier Launches New Pharmapendium, Empowering Pharma Companies to Bring Novel Drugs to Market Faster and Increase Success of Regulatory Submissions
October 10, 2023
London, United Kingdom--(Newsfile Corp. - October 10, 2023) - Elsevier, a global leader in information and data analytics, has launched...
Via
Newsfile
Topics
Animal Testing
Exposures
Animal Testing
Product Safety
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
October 09, 2023
Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities.
Via
MarketBeat
Obesity Drug Boom, Split Make This Stock a Heavy Bargain
October 09, 2023
Ozempic users may be losing their appetites for sweets…but Novo Nordisk is one Danish treat that the market may only get hungrier for.
Via
MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Vericity, Inc. (Nasdaq - VERY), POINT Biopharma Global, Inc. (Nasdaq - PNT), Blue Apron Holdings, Inc. (Nasdaq - APRN), Chico’s FAS, Inc. (NYSE - CHS)
October 03, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
October 02, 2023
Via
AB Newswire
Topics
Death
Exposures
Death
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.